HERA has signed a joint procurement framework contract for the supply of Paxlovid
The Commission's Health Preparedness and Response Authority (HERA) has signed a joint procurement Framework Contract for the supply of Paxlovid, a SARS-CoV-2 protease inhibitor oral treatment for patients with COVID-19 at risk of developing severe disease. The contract is signed with the pharmaceutical company Pfizer and will run for an initial period of 12 months.
Thirteen EU and EEA Member States and EU candidate countries are participating in the procurement. They will be able to purchase up to 3,427,517 five-day treatment courses of the orally administered Paxlovid.
Paxlovid can be used for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Paxlovid is expected to be effective against the current circulating and dominant strains of the virus.